| Name | Title | Contact Details |
|---|
Vita Health Products is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In July 2014, Genoa Healthcare and QoL meds combined to create Genoa, a QoL Healthcare Company, the nation`s leading behavioral health specialty pharmacy company. This merger brought together two pharmacy organizations with proven track records for excellent service to individuals with mental illness. Both companies had strong reputations for outstanding customer service, flexibility and delivering true value to their consumers and partners. By uniting their strengths – like best practices and expertise – the combined company was able to better serve individuals and the health organizations that care for them over the past year. Genoa has been serving the behavioral health community for over 15 years. The company now provides specialty behavioral health and long-term care pharmacy services to more than 500,000 individuals annually, operating over 285 pharmacies in 39 states and the District of Columbia and filling more than 9 million prescriptions per year. Although Genoa specializes in serving behavioral health consumers, we are a full-service pharmacy. This means we take care of all the medication needs of our consumers, including prescriptions written by psychiatrists, primary care providers, or other specialty prescribers. Genoa remains flexible to the many behavioral health and primary care delivery models across the country and developed services within our pharmacies to meet the needs of those specific models. None of our service models or pharmacies are the same. We take pride in not being a "cookie cutter" organization, and continue to seek opportunities nationwide to help behavioral health communities with their pharmacy services.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
For over 35 years, Davis Vision, an award-winning specialty Vision Health Plan, has provided custom designed vision and eyecare programs to corporations, union trust funds and managed care organizations across the country.
Devon Medical is a King Of Prussia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.